Form 4: Nurix CSO Gwenn Hansen Granted Equity Awards

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, was granted 93,750 employee stock options and 42,875 restricted stock units.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NRIX), was granted equity awards on February 10, 2026.
• The awards include 93,750 employee stock options with an exercise price of $16.45 per share.
• The stock options will vest monthly at a rate of 1/36 of the total shares, starting March 10, 2026, and will be fully vested by February 9, 2029, contingent on continued service.
• The stock options have an expiration date of February 9, 2036.
• Additionally, 42,875 Restricted Stock Units (RSUs) were granted.
• Each RSU represents a contingent right to receive one share of Nurix Therapeutics' common stock.
• The RSUs will vest quarterly at a rate of 1/12 of the total award over three years, with the first quarterly increment vesting on July 30, 2026, also contingent on continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for corporate governance and executive alignment, as it ties a key executive's compensation directly to the company's long-term success, though it does not directly reflect operational performance.

Positives

• The grant of equity awards aligns the Chief Scientific Officer's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard method for attracting and retaining key executive talent in the biotechnology sector.

Negatives

• The awards do not provide immediate liquidity or cash value to the reporting person.
• The vesting schedules tie a significant portion of the compensation to future service, meaning the awards could be forfeited if the reporting person's service terminates prematurely.

Risks

• The value of the stock options and RSUs is subject to the future market price fluctuations of Nurix Therapeutics' common stock.
• The vesting of these awards is contingent upon the reporting person's continued provision of service to the Issuer, posing a risk of forfeiture if employment ceases.

Future Outlook

The equity grants are designed to incentivize the Chief Scientific Officer's long-term commitment and contributions to Nurix Therapeutics, aligning future performance with personal compensation.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options and restricted stock units, are a prevalent and critical component of executive compensation packages within the biotechnology industry. This practice is essential for attracting and retaining top scientific and leadership talent, fostering a long-term perspective, and aligning executive incentives with the company's strategic goals and shareholder value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that these types of equity grants, featuring multi-year vesting schedules, are standard compensation practices for senior executives in the biotechnology sector.
• The structure is comparable to compensation strategies employed by other innovative biotech firms, such as Moderna or BioNTech, for similar roles, aiming to incentivize sustained commitment and performance over several years.

Related Party Transactions

• The filing details the grant of equity awards (employee stock options and restricted stock units) to Gwenn Hansen, the Chief Scientific Officer, which constitutes a transaction between the company and a related party (an officer).

Stakeholder Impact

• Shareholders: The equity grants aim to align the Chief Scientific Officer's interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: The compensation structure for a key executive can set a precedent or reflect the company's overall approach to incentivizing its talent.
• Management: The awards provide a significant incentive for the Chief Scientific Officer to remain with the company and contribute to its success over the vesting period.

Next Steps

• Gwenn Hansen's continued provision of service to Nurix Therapeutics is required for the vesting of both the stock options and restricted stock units.
• Shares of common stock will be delivered to the reporting person following the vesting of the RSUs.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Gwenn Hansen, Chief Scientific Officer, CSO, Employee Stock Option, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, Insider Transaction, SEC Form 4